We have prospectively evaluated the efficacy of realtime PCR-guided preemptive therapy for CMV diseases in allogeneic hematopoietic stem cell transplant recipients with grades II-IV acute GVHD. The dose of ganciclovir was adjusted according to the viral load determined by real-time polymerase chain reaction (PCR). On detecting CMV reactivation in the plasma, ganciclovir was initiated at a dose of 5 mg/kg body weight once daily, and the dose was increased to twice daily if viral load continued to increase after initiating ganciclovir. In 39 evaluable patients, CMV reactivation assessed by real-time PCR became positive in 30 (77%). One developed CMV gastroenteritis before PCR became positive. Thus the remaining 29 patients were treated preemptively with ganciclovir. The dose of ganciclovir was increased in 12 patients (41%) of preemptively treated patients for increasing viral load. CMV diseases were diagnosed in two patients (one gastroenteritis and one retinitis), and late CMV disease was diagnosed in one patient (gastritis). The treatment was generally well-tolerated, but three patients (10%) developed neutropenia (neutrophil count less than 1.0 × 10 9 /l). In conclusion, real-time PCR-guided preemptive therapy with decreased dose of ganciclovir is feasible and does not increase the frequency of CMV diseases if the dose is adjusted according to the viral load.
geneic hematopoietic stem cell transplantation. 1 The mortality of CMV diseases, particularly CMV pneumonitis, remains high even after the introduction of combined therapy with ganciclovir and immunoglobulin. 2, 3 Several studies have shown that the prophylactic use of ganciclovir successfully prevented CMV diseases, but survival benefit of this approach has not been clearly demonstrated because of its toxicities, particularly neutropenia. [4] [5] [6] In addition, the prophylactic use of ganciclovir has been associated with increased incidence of late CMV diseases. It probably delays the reconstitution of CMV-specific T cell responses. 7 Therefore, many investigators have focused on preemptive therapy, an approach to treat only patients with proven CMV infection. [8] [9] [10] Although several diagnostic methods are available to detect CMV infection, rapid, sensitive, quantitative, and reliable methods are essential for this approach in order to detect CMV infection before CMV disease develops. 11 CMV antigenemia is one of the most widely used methods to detect CMV infection, and antigenemia-guided preemptive therapy has been shown to be effective in preventing CMV diseases. 6, [12] [13] [14] However, we and others have demonstrated that antigenemia-guided preemptive therapy did not completely prevent the occurrence of CMV diseases other than pneumonitis. 6, 13 In addition, the assay has some other disadvantages. It is relatively time-consuming, involves subjective components in the interpretation of slides, and needs sufficient granulocytes. In the present study, we have prospectively evaluated the efficacy of realtime PCR-based preemptive therapy for CMV diseases following allogeneic hematopoietic stem cell transplantation (HSCT). This study is unique in two ways. First, in order to avoid the overtreatment attributable to higher sensitivity of this method, we only focused on the patients who are at high risk of developing CMV infection, defined as patients with grades II-IV acute graft-versus-host disease (GVHD). Second, ganciclovir was started at a lower dose (5 mg/kg/day), which was then increased subsequently according to the viral load.
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Patients and methods
Patients and transplant procedures
CMV-seropositive patients or CMV-seronegative patients with seropositive donors, who underwent allogeneic bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT) at Keio University Hospital, were enrolled into this study. Patients receiving nonmyeloablative conditioning or T cell-depleted grafts were excluded. All patients received CMV hyperimmunoglobulin (5 g) once a week starting from day 1 until day 100. Blood products were not screened for CMV antibody, but were filtered to remove leukocytes before transfusion. Conditioning regimens and acute GVHD prophylaxis were selected according to the ongoing protocols. Acute GVHD was graded according to the published criteria. 15 All patients with grades II-IV acute GVHD were treated with steroids in addition to cyclosporin A (CsA) or tacrolimus, and anti-thymocyte globulin (ATG) in cases of grades III-IV GVHD refractory to steroids.
Dose-adjusted preemptive therapy
After engraftment, patients were monitored for CMV infection with plasma real-time PCR once a week. Patients receiving intensive immunosuppressive therapy such as high-dose glucocorticoid or ATG were monitored twice weekly as possible after real-time PCR became positive. If CMV-DNA was detected in plasma (more than 20 copies/100 l) in patients with grades II-IV acute GVHD, defined as high-risk patients, ganciclovir was started at a dose of 5 mg/kg body weight once daily for 14 days. If viral load continued to show any increase even after initiation of ganciclovir administration, the dose of ganciclovir was increased up to 5 mg/kg twice daily. If CMV remained detectable after this initial therapy, ganciclovir (5 mg/kg) was continued at the same dose, every 2 or 3 days according to the viral load until CMV became undetectable. Monitoring was continued until intensive immunosuppressive therapy, particularly glucocorticoid, was discontinued. When CMV diseases were diagnosed, ganciclovir at the dose of 5 mg/kg twice daily was initiated immediately. Neutropenia, defined as absolute neutrophil count less than 1 × 10 9 /l for 2 consecutive days during or after ganciclovir therapy, was initially treated with filgrastim at a dose of 5 g/kg per day. If neutropenia persisted even after initiating filgrastim, ganciclovir was discontinued and foscarnet at a dose of 90 mg/kg once or twice daily was given. If CMV became detectable again after successful clearance, ganciclovir was reinitiated and its dose was adjusted according to viral load as well as ongoing immunosuppressive therapy and neutrophil counts. The dose of anti-viral agents was also adjusted according to serum creatinine level or creatinine clearance. CMV antigenemia was also examined on the same days as monitoring by real-time PCR.
Real-time PCR
Real-time PCR was performed as previously reported. 13, 16 Briefly, DNA extracted from 100 l of plasma using a QIAamp Blood Mini Kit (Qiagen, Valencia, CA, USA) was subjected to PCR. Sequences of PCR primers and probe were selected from the US17 region of CMV AD169. The sequences of forward and reverse primers were 5Ј-GCGTGCTTTTTAGCCTCTGCA-3Јand5Ј-AAAAGTTTGTGCCCCAACGGTA-3Ј, respectively. The Taqman probe selected between the primers was duallabeled with FAM (6-carboxyfluorescein) at the 5Ј-end as a reporter dye and with TAMRA (6-carboxy-teremethyl-rhodamine) at the 3Ј-end as a quenching dye, whose sequence was 5Ј-TGATCGGCGTTATCGCGTTCTTGATC-3Ј. The PCR reaction was performed by using TaqMan Universal PCR Master Mix (PE Biosystems, Foster City, CA, USA) and nuclease degradation of the probe was detected as an increase in fluorescent intensity by ABI PRISM 7700 (PE Biosystems). The quantification of CMV was carried out with a serially diluted standard ranging from 10 to 1 × 10 7 copies/well and the gene copy numbers calculated by Sequence Detection System ver.1.6.3. software (PE Biosystems). The sensitivity was 20 copies per well.
CMV antigenemia assay
Antigenemia assay was performed according to previously reported methods. 17 Briefly, EDTA-treated whole blood samples were fractionated by dextran-sedimentation and lysis of erythrocytes. The granulocytes were then centrifuged to prepare a cytospin slide (150 000 granulocytes per slide). The cells were then fixed with formaldehyde, sequentially immunostained by monoclonal antibodies C10/C11 (Clonab CMV; Biotest, Dreieich, Germany), and reacted with goat alkaline phosphatase-labeled anti-mouse immunoglobulin (Yuka Medias Co, Ibaraki, Japan). The examination was performed in duplicate.
Definition of CMV diseases
CMV pneumonitis was defined as interstitial infiltrates on chest radiograph accompanied by histologic demonstration of CMV in lung biopsy material or a positive CMV culture from bronchoalveolar lavage fluid. CMV gastroenteritis was defined as gastrointestinal symptoms accompanied by histologic demonstration of CMV or a positive CMV culture from biopsy material obtained by endoscopy. CMV retinitis was diagnosed based on characteristic retinal changes. Late CMV diseases were defined as those occurring later than 100 days after transplant.
Statistical methods
The difference between the two groups was assessed by the Mann-Whitney test. P values less than 0.05 were accepted as statistically significant. The Spearman rank correlation coefficient was calculated to compare the quantitative results of real-time PCR and CMV antigenemia.
Results
Study population
Thirty-nine CMV-seropositive patients or seronegative patients with seropositive donors who developed grades II-IV acute GVHD following allogeneic hematopoietic stem cell transplantation at Keio University Hospital were evaluable. The patient characteristics are shown in Table 1 .
Real-time PCR-guided preemptive therapy
Among the 39 patients with grades II-IV acute GVHD, 29 patients (74%) yielded positive results in real-time PCR, and were preemptively treated with ganciclovir at a dose of 5 mg/kg once daily ( Table 2 ). The median day post transplant of the first detection of CMV was day 34 (range16-62). One patient, in whom real-time PCR became positive on day 30, developed CMV gastroenteritis on day 20. The patient was treated therapeutically with ganciclovir at a dose of 5 mg/kg twice daily. The dose of ganciclovir was increased up to 5 mg/kg twice daily because of increased viral load in 12 (41.3%) of 29 preemptively treated patients. The median value of the initial viral load was 60 copies per 100 l of plasma in patients receiving 5 mg/kg/day of ganciclovir (n = 17), and was 55 in those receiving increased dose of ganciclovir (n = 12). The difference was not significant. The median duration of preemptive treatment was 20.5 days (range 14-95 days). Foscarnet was used after discontinuation of ganciclovir because of persistent neutropenia in three patients, and was concomitantly CMV = cytomegalovirus; R = recipient; D = donor; TBI = total body irradiation; CY = cyclophosphamide; CA = cytarabine; VP-16; etoposide; Bu = busulfan; GVHD = graft-versus-host disease; CsA = cyclosporin A.
Bone Marrow Transplantation used with ganciclovir because of primary treatment failure with ganciclovir alone in one patient.
Incidence of CMV diseases
In addition to the patient described above, two patients developed CMV diseases. Before day 100, one developed CMV retinitis around day 60. In this patient, real-time PCR became positive on day 13 and became undetectable after preemptive therapy. The PCR became positive again on day 50, and ganciclovir at a dose of 5 mg/kg every other day was reinitiated. The other patient developed late CMV gastritis around day 120. In this patient, real-time PCR became positive on day 29 and was successfully managed with preemptive therapy. This patient was treated with high-dose steroid therapy for refractory acute GVHD and subsequent extensive chronic GVHD. All of the three patients who developed CMV diseases were successfully treated with ganciclovir, and no death related to CMV diseases was observed. None of the evaluable patients developed CMV pneumonitis.
Incidence of neutropenia
Of 30 patients treated with ganciclovir either preemptively or therapeutically, three patients (10%) developed neutropenia (neutrophil count Ͻ1 × 10 9 /l), and two patients developed septicemia during neutropenia. In one of the two patients, secondary graft failure was diagnosed and septicemia was fatal despite the treatment with filgrastim and appropriate antibiotics. However, there was no clear causative relationship between secondary graft failure and ganciclovir.
Comparison of real-time PCR and CMV antigenemia
The qualitative results of real-time PCR compared with CMV antigenemia on an individual basis showed a high Table 2 Results of preemptive therapy for CMV disease in patients with grades II-IV acute GVHD (n = 39) Table 3 ). In two preemptively treated patients with positive real-time PCR, CMV antigenemia had remained undetectable throughout the study period. Among the other 28 patients with positive real-time PCR, real-time PCR became positive earlier than CMV antigenemia in 16 patients, both methods became simultaneously positive in nine patients, and CMV antigenemia became positive earlier than real-time PCR in three patients (Table 3) . Comparison of the quantitative results of both methods from 592 samples showed a correlation coefficient of 0.748 (P Ͻ 0.0001) (Figure 1 ).
Real-time PCR
Discussion
In the present study, we evaluated the efficacy and safety of a dose-adjusted preemptive therapy based on real-time PCR for CMV diseases in selected high-risk patients fol- Real-time PCR (copies/100 ml) lowing allogeneic HSCT. Based upon our previous experience and other reports, high-risk patients were defined as patients developing grades II-IV acute GVHD, 1,13,18 who received intensive immunosuppressive therapy including high-dose steroid therapy and ATG in addition to CsA or tacrolimus. The reason why we focused only on high-risk patients was to avoid overtreatment due to the high sensitivity of real-time PCR. Furthermore, in order to assess whether the dose of ganciclovir could safely be reduced using this sensitive assay, the initial dose of ganciclovir, which was adjusted according to the viral load after initiating the treatment, was reduced by 50% (5 mg/kg/day) as compared to previous reports. 6, [12] [13] [14] Of 39 high-risk patients, 30 patients had positive results in real-time PCR. The dose of ganciclovir was increased to 10 mg/kg/day in about 40% of preemptively treated patients because of progressively increasing viral load. The median values of initial viral load were not significantly different between patients receiving low-dose and an increased dose of ganciclovir, which suggests that initial viral load is not indicative of subsequently increasing viral load. The three patients with early or late CMV diseases were successfully treated with ganciclovir, and no CMV-related mortality was observed. Thus, our preemptive therapy based on real-time PCR effectively eradicated the CMV-related mortality, but did not completely prevent the occurrence of CMV diseases.
Treatment with low-dose ganciclovir may increase the risk of developing resistant virus. In this study, ganciclovirresistant CMV was not observed after durable ganciclovir therapy. Only one case of primary treatment failure with ganciclovir alone received foscarnet in combination with ganciclovir. Since viral load was primarily unmanageable with ganciclovir in this patient, it is unlikely that resistance to ganciclovir was provoked by the administration of lowdose ganciclovir.
Although the recent strategies for CMV infection and disease have focused on preemptive therapy, 10 some important problems have been pointed out. First, regarding the determination of the most suitable methods to detect CMV infection: While CMV antigenemia assay has been recognized as a sensitive and useful monitoring assay, 19 several disadvantages have been pointed out. Some promising results have recently been reported using flow cytometry to overcome these disadvantages, although they are not fully satisfactory. [20] [21] [22] Numerous publications have shown the use of a variety of molecular amplification methods. [23] [24] [25] [26] [27] [28] In our previous report, we retrospectively demonstrated that quantitative real-time PCR was more sensitive and correlated with the effects of antiviral treatment better than CMV antigenemia in a small number of patients with CMV gastroenteritis. 13 In this prospective study with more patients, we confirmed our previous observation and that real-time PCR-guided preemptive therapy more effectively but not completely prevented the occurrence of CMV diseases.
Regarding the ideal sample material for PCR, ie plasma (or serum) or leukocytes (or whole blood), remains to be elucidated. Although the use of plasma may lead to a loss of sensitivity as compared with that of leukocytes, it detects only free virions indicative of active viral replication with a higher clinical relevance. Thus, it could minimize overtreatment and further discriminate between active infection and latent infection. Although the comparative results of different methods and sample materials have been reported, it seems difficult to draw definitive conclusions as these different methods have been evaluated in different patient settings (recipients of HSCT or solid organ transplant, and acquired immunodeficiency syndrome patients). [29] [30] [31] [32] [33] Further studies are therefore required to determine the respective diagnostic values of each method and to refine preemptive therapy by the most suitable method in HSCT recipients. We prospectively compared the results of plasma real-time PCR and CMV antigenemia assay. On the whole, real-time PCR was more sensitive than antigenemia assay. The fact that CMV antigenemia did not precede the onset of disease in three patients with CMV disease also reinforces this conclusion. Regarding the quantitative results, there was a good correlation between the two methods with some discordant results. The likely explanation for this is primarily that the two methods are very different markers of virus replication, detecting free virions in plasma and virus protein in granulocytes, and have different levels of sensitivity.
Neutropenia was observed in 10% of preemptively or therapeutically treated patients in this study. The incidence of neutropenia seems lower than that in our previous report using a higher dose of ganciclovir as the starting dose (17%). 13 However, one patient developed secondary graft failure, although its causative relationship with ganciclovir administration was not definite. Although preemptive therapy could reduce ganciclovir-related neutropenia, the possibility of recurrent CMV infection after successful management with preemptive therapy, and longer use of ganciclovir for recurrent CMV infection and its side-effects should also be considered as part of the trial. In this study, one patient developed CMV retinitis once after CMV infection was successfully controlled by preemptive therapy. In addition to ganciclovir therapy, intensive immunosuppressive therapy including high-dose steroids and ATG could be a risk factor for recurrent CMV infection and subsequent late CMV diseases due to delaying CMV-specific immune reconstitution. 34, 35 To totally evaluate the efficacy and disadvantages of a reduced dose of ganciclovir, a comparative study should be performed.
In conclusion, our preemptive approach based on realtime PCR with adjusted dose of ganciclovir effectively but not completely prevented the occurrence of CMV diseases. Although our strategy targeted only high-risk patients with proven CMV infection, it is possible that some patients are still overtreated. Therefore, further modification of this approach should focus on the combination with the respective patients' CMV-specific immune reconstitution, whose quantification is reportedly available. 36 
